Heart failure & cardiomyopathiesCohort study

Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: A report from the CHART-2 Study

EuropacePublished

  • Prospective cohort study (CHART-2 registry analysis)
  • multivariable Cox proportional hazards model

Authors' conclusion

In patients with HFpEF, AF progression is significantly associated with adverse outcomes, particularly worsening heart failure.

Study context

Population
Patients with heart failure with preserved ejection fraction (HFpEF) and paroxysmal atrial fibrillation (AF) in the CHART-2 Study (Tohoku District, Japan)median age 72 y, 36% female
Participants
718 patients
Exposure
AF progression vs no AF progression
Outcome
Incidence of AF progression (transition from paroxysmal to persistent AF) and its clinical impact
Follow-up
Median 6.0 years

Main finding

As reported in the abstract

AF progression · median follow-up 6.0 years (IQR 3.0-10.2)

AF progression occurred (n = 105)

14.6%

Cumulative incidence of AF progression at 10 years

16.7%

Observational data: associations, not effects.

Further findings

Predictors of AF progression (multivariable Cox model)

ComparisonHR (95% CI)P value
previous hospitalization for heart failure1.74 (1.16–2.60)P = 0.007
OutcomeHR (95% CI)P value
Predictors of AF progression (multivariable Cox model) — left atrial diameter (per 5-mm increase)1.37 (1.20–1.55)P < 0.001

Worsening HF associated with AF progression

Comparisonadjusted HR (95% CI)P value
AF progression1.68 (1.18–2.40)P = 0.004
Worsening HF associated with AF progression — Worsening HF within 1 year following AF progression
27 cases (26%)

Original publication

Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: A report from the CHART-2 Study. Europace. Published 16 August 2024. doi:10.1093/europace/euae218

Summarised from the published abstract; every number is checked against it